Home » Boehringer Ingelheim, Cenix in RNAi Research Deal

Boehringer Ingelheim, Cenix in RNAi Research Deal

Feb 02, 2009

NEW YORK (GenomeWeb News) — Cenix BioScience will support Boehringer Ingelheim with RNAi-focused contract research services for its therapeutic drug programs under a new agreement, Cenix said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Articles

May 02, 2014

UK Data Analysis Firm Congenica Wins $337K Genomics England Award

Oct 02, 2014

Alnylam Initiates Observational Study of Hepatic Porphyria Patients

Premium
Aug 28, 2014

Cenix, Metanomics Reach Research Agreement

May 08, 2014

Cenix Inks Research Deal with Bayer

Premium
Oct 16, 2014

With RNAi Screening Tech, Startup Recursion Aims to Repurpose Drugs for Rare Diseases

Premium
Jul 10, 2014

Ventana to Develop CDx for Merck KGaA

The Scan

Ancient Wheat

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

'High School Never Ends'

Joel Achenbach explores at National Geographic why people find science difficult to believe.

This Week in Science

In Science this week: gene linked to expansion of the human neocortex, and more.

Bit of an Increase

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

What's Popular?

In miRNA/RNAi

  1. New RNAi Technique Shows Complete Crop Protection from Key Pest

    Premium

  2. New Study Expands Number of microRNAs in Human Genome

    Premium

  3. UMD Study Uncovers New Mechanism of Transgenerational RNAi in C. elegans

  4. As CRISPR-Cas9 Technology Sets to Take Off, Uncertainty Swirls Around IP Landscape

  5. Gradalis Moves Cancer Vaccine with RNAi Component into Phase III

    Premium

Sponsorships

Privacy Policy.  Copyright © 2015 Genomeweb LLC.  All Rights Reserved.